Laekna, Inc. (LAEKF)

Market Cap	392.85M -57.2%
Revenue (ttm)	15.26M
Net Income	-32.79M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296
Open	0.7300
Previous Close	0.9412
Day's Range	0.7300 - 0.7300
52-Week Range	0.7300 - 2.2100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 83
• Stock Exchange: OTCMKTS
• Ticker Symbol: LAEKF

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 11, 2026

Data Sources Report a data error